Migraine disorders are among the
most common disorders of the nervous system, it has been almost seen in adult
population. Furthermore, North America holds the largest share in the Migraine
Drug Market as it holds a large number of ageing population, according to
the U.S. Census Bureau in 2013 the aging population was around 14.1%As per
World Health Organization (WHO) in 2016, globally it has been estimated that
50% of migraine disorders was found and percentage of this disorders is found
high in women due to the hormonal influences. Also, according to the National
Headache Foundation (NHF), people from the U.S. spend more than US$ 4 billion
annually on drugs in the treatment of migraine pain. The factors influencing
for migraine drugs market include increase in awareness about migraine
treatment drugs and advancement in technology in the development of migraine
drugs.
Migraine is a neurological
disorder that causes severe pain in head and results in nausea, vomiting, and
extreme sensitivity to light and sound. The common types of migraine are with
aura and without aura that means classical migraines and common migraines.
Women are more prone to this disease than men. Therapeutic agents such as
anti-inflammatory drugs (NSAIDs), for example aspirin, ibuprofen, sumatriptan,
zolmitriptan, naproxen, anti sickness medicines and many more drugs are used to
cure or lower the migraine. The symptoms of migraine can begin in childhood or
in adulthood and it may progress through four stages such as prodrome, aura,
headache and postdrome. Whereas aura occurs before or during a migraine, it is
a symptom of nervous system that usually leads to visual disturbance such as
flashes of light or zigzag vision. In this visual disturbance, around 20 to 60
minutes of vision loss occurs, also the pins, needles sensation in arms can be
felt. Furthermore, it may lead to difficulty in speaking and can cause for uncontrollable
movements of body.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/575
The factors that trigger
migraines include hormonal changes in female body, salty food and processed
food, alcohol drinks, medications such as oral contraceptive and vasodilators
for example nitroglycerin can cause migraines. Latest technology such as a new,
smartphone controlled wireless patch has been devised that uses electrical
stimulation to reduce the pain of migraines is going to be a revolutionary for
migraine patients,
Emerging drugs expected to boost
the growth of migraine drugs market in the near future
The launch of new drugs in market
is expected to boost the margarine drugs market in the forecast period. For
example, the Indian pharmaceutical company Cadila Healthcare Ltd. (Zydus
Cadila) received the final approval on June 20, 2017, from the Food and Drug
Administration (FDA) to market Eletriptan Hydrobromide tablets (20 mg and 40
mg), which is used in the treatment of migraine.
Furthermore, another Indian
pharmaceutical company Novartis has filed its migraine drug erenumab with the
European Medicines Agency (EMA) on June 21, 2017. Which is expected to put
other pharmaceutical companies into racing to develop a new drug for the
treatment of migraine.
Teva Pharmaceuticals Industries
Ltd. an Israeli multinational pharmaceutical company which expected to file
approval for fremanezumab (TEV-48125) drug by Food and Drug Administration
(FDA) later this year (2017). This drug will be used in chronic migraine and
the episodic migraine treatment, and this drug is expected to commercialize in
market by the second half of 2018.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/migraine-drugs-market-575
According to the Migraine
Research Foundation (MRF), migraine is a common neurological disease, around 38
million population including men, women and children in the U.S and 1 billion
population around the globe is affected by it as of 2017. Excessive consumption
of alcohol and increase in consumption of oral contraceptives significantly
increases number of migraine disorder cases.
Migraine Drugs Market Key Players
Includes:
The increased focus on drug
development expected to support the market expansion of migraine drugs market
players. There are various players across the globe running into the
competition includes Endo International plc, Pfizer Inc., Aegis Therapeutics,
LLC., Aeriel BioPharma, Alder BioPharmaceuticals Inc., Amgen Inc., Astellas
Pharma Inc., CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd.,
IntelGenx Corp., Johnson & Johnson, Kowa Pharmaceuticals America, Luitpold
Pharmaceuticals, Teva Pharmaceutical Industries LTD., Valeant Pharmaceuticals International,
Inc., WINSTON PHARMACEUTICALS, Inc., Zogenix Inc., Abbott Laboratories,
AstraZeneca plc, and GlaxoSmithKline plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/575
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment